NCT02044848View on ClinicalTrials.gov

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Secukinumab

DRUG

Placebo

Placebo

Trial Locations (2)

10032

Novartis Investigative Site, New York

98122

Novartis Investigative Site, Seattle

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT02044848 - Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter